Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL25296246 | 0.95 | OPRM1 (0.46) | AKR1C1OPRM1AKT1HDAC1MME | |
| SCHEMBL28173281 | 0.87 | AKT1 (0.44) | OPRM1AKT1HDAC1MME | |
| SCHEMBL2221 | 0.87 | AKR1C1 (0.55) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL28173275 | 0.86 | AKT1 (0.43) | OPRM1AKT1HDAC1MME | |
| SCHEMBL3910628 | 0.85 | AKR1C1 (0.53) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| SCHEMBL30711945 | 0.84 | AKT1 (0.45) | OPRM1AKT1HDAC1MMEKMT2A | |
| Water SCHEMBL3910626 | 0.83 | AKR1C1 (0.52) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| SCHEMBL9966557 | 0.83 | AKR1C1 (0.68) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| SCHEMBL373567 | 0.83 | AKR1C1 (0.68) | AKR1C1OPRM1HDAC1KMT2A | |
| SCHEMBL1492737 | 0.83 | AKR1C1 (0.62) | AKR1C1HDAC1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-118510751-A | Method for producing amide compound | 中外制药株式会社 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023132352-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | AKR1C1 427/4885OPRM1 494/4885AKT1 1615/4885 |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | AKR1C1 2289/4885OPRM1 361/4885AKT1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.